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Abstract: Messenger RNA encodes cellular function and phenotype. In the context of human 
cancer it defines the identity of malignant cells and diversity of tumor tissue. We studied 
72,501 single cell transcriptomes of human renal tumors and normal tissue from fetal, 
pediatric and adult kidneys. We matched childhood Wilms’ tumor with specific fetal cell 5 
types, thus providing evidence for the hypothesis that Wilms’ tumor cells are aberrant fetal 
cells. In adult renal cell carcinoma we identified a canonical cancer transcriptome that 
matched a little known subtype of proximal convoluted tubular cell. Analyses of the tumor 
composition defined cancer-associated normal cells and delineated a complex VEGF 
signaling circuit. Our findings reveal the precise cellular identity and composition of human 10 
kidney tumors. 
 
One Sentence Summary: Single cell mRNAs of 72,501 normal and cancerous kidney cells 
reveals the cellular identity of childhood and adult tumors.  
 15 
Main Text: Cancer cell identity is defined by morphological appearance, tissue context, and 
marker gene expression. Single cell transcriptomics refines this cellular identity on the basis of a 
comprehensive and quantitative read out of messenger RNA.  Precise cellular transcriptomes may 
reveal a tumor’s cell of origin and the transcriptional trajectories underpinning malignant 
transformation (1). 20 
 
We sought to define the identity of normal and cancerous human kidney cells from a catalogue of 
72,501 single kidney cell transcriptomes, integrated with tumor whole genome DNA sequencing 
(2). We studied Wilms’ tumor (n=3), clear cell (ccRCC; n=3) and papillary renal cell carcinoma 
(pRCC; n=1) in relation to healthy fetal (n=2), pediatric (n=3), adolescent (n=2), and adult kidneys 25 
(n=5), as well as ureters (n=4; Table S1)  
 
Normal tissue biopsies were taken from macroscopically normal regions of kidneys resected due 
to cancer (n=10) or for transplantation (n=2). We performed technical replicates of each biopsy 
and biological replicates, where clinically permissible (Table S1). We processed kidneys 30 
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immediately following resection, generating single cell solutions enriched for viable cells. We 
derived counts of mRNA molecules in each cell for further analyses, subject to quality control (2).  
 
We split 72,501 fetal, normal, and tumor cells into immune and non-immune cell compartments 
(Fig. S1).  Using a community detection algorithm (2), transcriptomes were further segregated into 5 
distinct clusters of cells (Table S2).  We next generated a reference map of normal mature and 
fetal cells, assigning an identity to each cluster, by cross-referencing cluster-defining transcripts 
with canonical markers curated from the literature (Table S3). Ambiguous clusters were not 
included in the reference map and are presented in Fig. S2-S8. Highly specific cluster-defining 
transcripts (potential cell markers) are appended (Table S4).  10 
 
Amongst 42,809 non-malignant cells, 37,951 mature kidney cells represented epithelial cells from 
distinct micro-anatomical regions of the nephron, with a large proportion of proximal tubular cells 
(Fig. 1A-C, Fig. S4). Furthermore, there were fibroblasts, myofibroblasts, and vascular endothelial 
cells, i.e. glomerular endothelium, ascending and descending vasa recta (Fig. 1D, Fig. S2). 4,858 15 
fetal cells grouped into developing nephron cells (ureteric bud, cap mesenchyme, primitive 
vesicle) and fibroblasts, myofibroblasts, vascular endothelial and ganglion cells (Fig. 2A-C, Fig. 
S5).  
 
To determine transcriptional programs underlying nephrogenesis, we identified differentially 20 
expressed transcription factors in ureteric bud cells against cap mesenchyme and primitive vesicle 
cells (Fig. 2D). Furthermore, we applied pseudo-timing methods to identify transcription factors 
that define the transition from cap mesenchyme to primitive vesicle (Fig. 2D). Together, these 
analyses identified established, and unknown, transcription factors associated with nephron 
development, included as a reference for subsequent analyses of malignancy (Table S5).  25 
 
Having established the single cell landscape of healthy kidneys, we characterized the cellular 
identity of 6,333 non-immune (Fig. S7) and 17,821 immune (Fig. S8) tumor cells from Wilms’ 
tumor (n=3), ccRCC (n=3) and pRCC (n=1; Table S1). Children had received neoadjuvant 
cytotoxic treatment prior to nephrectomy, as per British practice. Although this pre-treatment 30 
reduced yield (Table S6), recovered cells represent therapeutically relevant surviving cancer cells 
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that determine the degree of adjuvant cytotoxic chemotherapy required (3). We used logistic 
regression to quantify the similarity between tumor and normal cell clusters, validated through 
intrinsic control populations (2). That is, the model found myofibroblasts from tumors matched 
myofibroblasts from mature and fetal kidneys (Fig. 3A) and no match for mast cells, a negative 
control population inserted into the training data. 5 
 
This similarity metric may be obfuscated by the phenotypic plasticity of tumor cells. We therefore 
developed a method to genotype individual cancer cells from mRNA reads using somatic copy 
number changes (Table S7; Fig. S9) defined by whole genome sequencing (Fig. S10). We 
validated genotyping calls by phasing single nucleotide polymorphisms across segments with 10 
altered copy number, testing for the presence of somatic single nucleotide variants, and comparison 
to control populations (Fig. S11-S14).  
 
Integrating genotyping and similarity analyses, we found that Wilms’ cells resembled fetal normal 
cells, evidencing that Wilms’ tumor represents aberrant fetal cells. We found different populations 15 
of Wilms’ tumor that matched ureteric bud and primitive vesicle cells (specific developing nephron 
populations) (Fig. 3A). One cluster (WF), composed of Wilms’ cancer cells and non-cancerous 
ccRCC fibroblasts, exhibited a fibroblast-myofibroblast transcriptome. In one case, we obtained 
an anatomically separate perilobar nephrogenic rest, thought to represent a precursor lesion of 
Wilms’. Like Wilms’ cancer cells, we observed that nephrogenic rest resembled ureteric bud or 20 
primitive vesicle. This suggests that the potential to generate the different cell states of the fetal 
nephron is acquired early, or was not lost, by the developing Wilms’ cancer, although this 
conclusion is based on only one sample.  
 
To validate the cellular identity of Wilms’ cells, we interrogated bulk transcriptomes of an 25 
independent series of 124 Wilms’ tumors for cellular signatures of ureteric bud and primitive 
vesicle (4, 5). We extracted specific markers expressed within ureteric bud or primitive vesicle 
cells and unexpressed within non-tumor cells (Table S8, (2)) and probed bulk transcriptomes for 
these cluster defining transcripts. As comparators to Wilms’ we included fetal, pediatric, and adult 
normal tissue bulk transcriptomes (n=135) and other childhood kidney tumors: 17 congenital 30 
mesoblastic nephroma and 65 malignant rhabdoid tumors. Corroborating the presence of these 
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cells in Wilms’, signatures of primitive vesicle and ureteric bud cells were seen in, and confined 
to, Wilms’ and normal fetal tissue (Fig. 3B).  
 
Placing Wilms’ tumor cells in pseudo-time revealed two transcriptional programs emanating from 
the ureteric bud: one branch predominantly describing the development of nephrogenic rest cells 5 
and the other of Wilms’ cancer cells (Fig. 3C). There was a significant overlap in the transcription 
factors underpinning these two programs (Fig 3D; Table S9) and normal nephrogenesis (p<10-4; 
hypergeometric test). This indicates that developmental relationships exist between Wilms’ tumor 
cells that have been adopted from normal nephrogenesis. Our analyses reveal the plasticity and 
fetal identity of Wilms’ cells and transcriptionally defines developmental cell states and 10 
trajectories that may harbor targetable vulnerabilities. 
 
Next we studied ccRCC and pRCC (type 1), including one case of von Hippel Lindau disease-
related ccRCC (Table S1). Matching ccRCC and pRCC with normal mature cells, we found that 
they retained transcriptional features of cluster PT1, a specific subtype of convoluted proximal 15 
tubular cell (Fig. 4A). Most (6/7) ccRCC clusters and all pRCC cells matched this particular PT1 
cell, indicating that it represents an RCC cell state that transcends the diversity of RCC cells within 
and across tumors.  Little is known about the nearest normal cell correlate of RCC, the PT1 cell, 
which has been identified to become more abundant in inflamed renal tissue (6).  
 20 
To validate the identity of the PT1 signature in RCC, we exploited the fact that they were defined 
by SLC17A3 and VCAM1 with absence of SLC7A13 within our data (Fig. 4B; Fig. S2). We 
measured these transcripts in an independent series of 1,019 publicly available bulk kidney tumor 
and normal tissue transcriptomes. High expression of SLC17A3 mRNA distinguished ccRCC and 
pRCC (type 1 and 2) from other types of RCC (p<10-4; Mann-Whitney test), whereas SLC7A13 25 
mRNA was significantly depleted in ccRCC/pRCC bulk transcriptomes versus normal (p<10-4; 
Mann-Whitney test), as were mRNAs representing other regions of the nephron (Fig. 4B). 
VCAM1, specific to PT1 within proximal tubules, was also significantly elevated across RCC bulk 
transcriptomes (p<10-4; Mann-Whitney test; Fig. 4B), with each individual RCC tumor exhibiting 
PT1 features (Fig. S15). Confocal microscopy demonstrated co-localization of VCAM1 and 30 
SLC17A3 in CA9+ cells, CA9 being a specific marker of ccRCC cells (Fig. 4C). Furthermore, we 
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studied the earliest precursor lesions of ccRCC: CA9+ proximal tubular cells residing in 
morphologically normal kidney, predisposed to ccRCC through pathogenic germline mutation of 
VHL. Examining tissue from three individuals, we identified CA9+/VCAM1+ clusters of proximal 
tubular cells (Fig. 4D). Similarly, tumors arising in these kidneys harbored CA9+/VCAM1+ cells 
(Fig. S16). As expected, VCAM1 was otherwise sparsely expressed on proximal tubular cells. 5 
Together these observations substantiate our proposition that PT1 cells are the nearest normal cell 
correlate of ccRCC cells. The presence of the PT1 signature in both ccRCC and pRCC may 
indicate a common origin of these tumors with divergent fates.   
 
Apart from the PT1 signature in pRCC and ccRCC, we found that one ccRCC cell cluster (cR7) 10 
matched PT3 cells and that pRCC cells exhibited an additional, weaker match with collecting duct 
cells (Fig. 4A). Neither signal was enriched in bulk transcriptomes (Fig. 4B). As our study was 
confined to type 1 pRCC, it is possible that we missed other pRCC cell types. 
 
Finally, we dissected the tumor microenvironment occupied by cancer-associated normal cells, 15 
comprised of immune cells, fibroblasts, myofibroblasts and vascular endothelial cells 
(predominately ascending vasa recta) (Fig. S7, S8, S17). Within these we studied VEGF signaling, 
an established target in RCC treatment (7, 8). The VEGF signaling circuit in renal tumors involves 
VEGFA secretion from RCC cells resulting in a response from endothelial cells (7, 8). Measuring 
expression of the key components of VEGF signaling, we identified tumor infiltrating 20 
macrophages as a further source of VEGFA (Fig. S18A), confirmed by confocal microscopy of 
ccRCC cells and flow cytometry of an independent ccRCC tumor (Fig. S18B,C,D). VEGF-
signaling receptors (KDR, FLT1, FLT4) were mainly expressed by one population of ascending 
vasa recta cells (Fig. S18A, cluster tE1). The other ascending vasa recta cluster, tE2, (Fig. S18A) 
exhibited lymphangiogenic VEGFC and FLT1. Furthermore, tE2 endothelial cells expressed high 25 
levels of ACKR1, a marker of venular endothelium promoting tissue migration of immune cells 
(9). Overall these findings delineate a complex VEGF signaling circuit within RCC tissue. 
 
By identifying specific normal cell correlates of renal cancer cells, our study moves our 
understanding of these malignancies beyond a notion of “fetalness” or an approximate micro-30 
anatomical region to a precise cellular, molecularly quantitative resolution. Our findings portray 
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the peak incidence of Wilms’ tumor in early childhood as a corruption of fetal nephrogenesis, in 
contrast to the life-long development of RCC in mature kidneys. Our study provides a scalable 
experimental strategy for determining the identity of human cancer cells. 
 
 5 
____________________
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Figure 1. Canonical cell types in normal human kidneys. 
(A) Illustration of nephron anatomy with cell clusters marked. 
(B) tSNE representation of 8,707 normal epithelial and vascular cells. Clusters are colored, 
uniquely labelled and emphasized with density contours.  Ambiguous clusters are de-emphasized 
and fully shown in Fig. S2. 5 
(C) Expression of canonical nephron specific genes (Table S3) in clusters from (A).  Colors give 
the fraction of cells expressing each gene in a cluster, scaled to have mean 0 and standard 
deviation 1 across all clusters. 
(D) Expression of clusters in (A) not shown in (C) and their canonical genes. 
 10 
 
 
 
 
15 
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Figure 2. Fetal cell types and nephrogenesis. 
(A) tSNE representation of 4,858 fetal epithelial and vascular cells, colored and labelled as in 
Fig. 1A.  
(B) Expression of markers of clusters in (A), colored as in Fig. 1C. 5 
(C) Expression of nephrogenesis markers from clusters in (A) with illustration of nephron 
development. Formation of nephrons emanates from the ureteric bud, which induces 
condensation of the overlying mesenchyme into the cap mesenchyme. The cap mesenchyme then 
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forms the primitive vesicle, the precursor of the glomerulus. The tubular system grows out from 
both ends of the fetal nephron: ureteric bud and primitive vesicle.   
(D) The expression of transcription factor which vary significantly (p<0.01; likelihood ratio test) 
along the pseudo-time trajectory defined using the CM and PV cells from (C), or differentially 
expressed between UB versus CM and PV. UB expression is shown in a separated block on the 5 
left. Within the right block, pseudo-time increases from left to right and rows are clustered and 
grouped by hierarchical clustering with canonical transcription factors of nephrogenesis 
highlighted (see Table S6). 
 
  10 
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Figure 3. Matching childhood tumors with normal fetal cells. 
(A) Similarity of Wilms’ tumor and cancer-associated normal cells to the reference fetal kidney 
map (Fig. 2A), with mast cells added as a negative control. Square boxes indicate sample 
Submitted Manuscript: Confidential 
17 
 
contribution. Colors represent the probability that the cluster identified in the column header is 
"similar" to the fetal cluster identified by the row label (2). 
(B) Expression of canonical tumor markers and representative UB and PV specific genes (Table 
S8) in RNA-seq from childhood cancers (yellow), normal tissue (blue) or adult cancers (green). 
MRT: malignant rhabdoid tumor; CMN: congenital mesoblastic nephroma. As positive controls, 5 
canonical tumor markers are shown: WT1 (Wilms’); CA9 (ccRCC).  
(C) Pseudo-time trajectory of all Wilms tumor and nephrogenic rest cell. Color indicates 
similarity of each cell to the PV or UB fetal population.  Jitter has been added to each point’s 
position with the original position plotted underneath in black (2). 
(D) Transcription factors identified as varying significantly along the pseudo-time trajectory in 10 
(C). The center of the heatmap corresponds to the cells at the top of (C) and then proceeding 
left/right along the arrows shown in (C). 
 
 
15 
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Figure 4. Matching adult tumors with normal mature kidney cells. 
(A) Similarity of adult cancer and cancer-associated normal cells to the mature kidney reference 
map (Fig. 1B), with mast cells added as a negative control. Square boxes indicate sample 
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contribution. Colors represent the probability that the cluster identified in the column header is 
"similar" to the normal cluster identified by the row label (2). 
(B) Expression of nephron specific genes in bulk RNA-seq as in Fig. 3B. pRCC samples are both 
type 1 and 2. 
(C) Confocal microscopy showing co-localization of PT1 markers (VCAM1, SLC17A3) in 5 
ccRCC cells (CA9). 
(D) Staining of a proximal tubular ccRCC precursor lesion (CA9) for the PT1 marker, VCAM1.  
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Materials and Methods 
 
Ethics statement 
 
Adult kidneys samples were collected from patients enrolled in the DIAMOND study; 
Evaluation of biomarkers in urological disease (NHS National Research Ethics Service reference 
03/018). Pediatric samples were acquired from patients enrolled in the ‘Investigating how 
childhood tumors and congenital disease develop’ (NHS National Research Ethics Service 
reference 16/EE/0394). Human fetal material was provided by the Joint MRC / Wellcome Trust-
funded (grant # 099175/Z/12/Z) Human Developmental BiologyResource  
(HBDR, http://www.hdbr.org; (10)), with appropriate maternal written consent and approval 
from the Newcastle and North Tyneside NHS Health Authority Joint Ethics Committee.  HDBR 
is regulated by the UK Human Tissue Authority (HTA; www.hta.gov.uk) and operates in 
accordance with the relevant HTA Codes of Practice. VHL kidneys were studied under UK 
ethics approval, REC 16/WS/0039 and 2002/6486. 
 
Tissue processing 
 
Kidney biopsies were taken by pathologists from normal and tumor regions. Where 
clinically permissible, separate cortical, medullary, pelvic, and ureteric biopsies were obtained. 
Otherwise a biopsy from the interface of medulla and cortex was taken. Tissues were sliced into 
approximately 30mm3 pieces of tissue and digested for 30 min at 37°C with agitation in a 
digestion solution containing 25µg/ml Liberase TM (Roche) and 50µg/ml DNase (Sigma) in 
RPMI (Gibco). Following incubation samples were transferred to a C tube (Miltenyi Biotec) and 
processed on a gentle MACS (Miltenyi Biotec) on programme spleen 4 and subsequently lung 2. 
The resulting suspension was passed through a 70µm cells strainer (Falcon), washed with PBS 
and live cells enriched using a Dead Cell Removal kit (Miltenyi Biotec) as per manufactures 
instructions. Enriched live cells were washed and counted using a hemocytometer with trypan 
blue. For fetal samples, whole kidneys were dissociated into single cell suspension following 
rapid 30 min collagenase treatment. Live, single cells were enriched for FACS-sorted DAPI- cell 
with further enrichment of immune cells by CD45 expression. Overall it took 5-6 hours from 
obtaining biopsies to generating single cell suspensions run on the Chromium 10X device. 
 
Comparison of human kidney tissue disaggregation methods 
 
It is likely that biases are introduced by different tissue dissociation protocols. We used a 
combination of mechanical and enzymatic dissociation (liberase) because mechanical 
dissociation alone introduced measurable biases as to which cell populations were captured (see 
Fig. S18). However, it should be noted that liberase itself can introduce transcriptional artefacts. 
 
In assessing dissociation methods, we used kidneys donated for transplant that were 
subsequently deemed unsuitable. Renal cortex samples were dissected, weighed (approximately 
0.64g per experiment) and sliced into 5mm3 pieces. Samples were digested in 50 µg/ml DNase 
(Sigma) in RPMI (Gibco) with or without 25 µg/ml Liberase TM (Roche) for 30 min at 37°C, 
with agitation. Following incubation, samples were transferred to a gentleMACS C Tube 
(Miltenyi Biotec) and processed using a gentleMACS Dissociator (Miltenyi Biotec) on program 
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spleen 4 and subsequently lung 2. The resulting suspension was passed through a 70 µm cells 
strainer (Falcon) and washed with PBS before leukocyte enrichment using a Percoll (Sigma-
Aldrich) density gradient. Cell counts per gram of tissue were calculated with the addition of 
123count eBeads (Invitrogen). Fc-Receptors were blocked using saturating concentrations of 
FcR blocking reagent (Miltenyi Biotec) and then stained with live/dead fixable Aqua 
(Invitrogen). Surface staining was performed with an anti-CD45- APC-eFluor780 (clone HI30, 
eBioscience), All samples were acquired on a BD LSR 4 laser Fortessa and data analysed using 
FlowJo v10. 
 
10X library preparation and sequencing 
 
The concentration of single cell suspensions were manually counted using a hemocytometer 
and adjusted to 1000 cells/ul or counted by flow cytometry. Cells were loaded according to 
standard protocol of the Chromium single cell 3’ kit in order to capture between 5000 cells/chip 
position (V2 chemistry). All the following steps were performed according to the standard 
manufacturer protocol. We used one lane of an Illumina Hiseq 4000 per 10x chip position. 
 
Flow sorting and VEGFA staining 
 
Tissue was obtained from a clear cell renal cell carcinoma immediately post nephrectomy, 
following histological confirmation. Samples were sliced into approximately 30mm3 pieces and 
digested for 15 min at 37°C, with agitation, in a digestion solution containing 25µg/ml Liberase 
TM (Roche) and 50µg/ml DNase (Sigma) in RPMI (Gibco). The resulting suspension was 
passed through a 70µm cells strainer (Falcon) and washed with PBS before blocking Fc-
Receptors using saturating concentrations of FcR blocking reagent (Miltenyi). Samples were 
stained with live/dead fixable Aqua (Invitrogen). Antibodies for surface staining were anti-CD3-
PerCP-Cyanine5.5 (clone SK7, eBioscience), anti-CD19-BV785 (clone HIB19, BioLegend), 
anti-CD14-PE-Cy7 (clone 61D3, eBioscience), anti-CD45-APC-eFluor780 (clone HI30, 
eBioscience), anti-HLA-DR V450 (clone L243, BD Bioscience), anti-CD68-FITC (clone KP1, 
Dako); and for intracellular antigens anti-VEGFA-PE (clone EP1176Y, Abcam). Cells were then 
fixed and permeabilised using FoxP3 intracellular kit (eBioscience) for intracellular analysis as 
per the manufacturers instructions. All samples were acquired on a BD LSR 4 laser Fortessa and 
data analyzed using FlowJo v10. 
 
Confocal microscopy 
 
Kidney samples were fixed in 1% paraformaldehyde (Electron Microscopy Services) / L-
lysine/ sodium periodate (both Sigma-Aldrich) buffer for 24h, followed by 8h in 30% sucrose in 
P-buffer. 30 um sections were cut on a cryostat, permeabilized and blocked in 0.1M TRIS, 
containing 0.1% Triton (Sigma), 1% normal mouse serum, 1% BSA (R and D systems). Samples 
were stained with the appropriate antibodies for 16h at 4°C in a wet chamber then washed 3 
times in PBS. Where required, samples were stained with secondary antibodies for 4h at room 
temperature in a wet chamber and washed 3 times in PBS. They were then stained with 
streptavidin in PBS for 10 minutes at room temperature, washed 3 times in PBS and mounted in 
Fluoromount-G® (Southern Biotech). Images were acquired using a TCS SP8 (Leica, Milton 
Keynes, UK) confocal microscope. Raw imaging data were processed using Imaris (Bitplane).  
4 
 
Antibodies/dilutions for immunofluorescence microscopy  
 
Antibodies and dilutions used are listed in Table S12. 
 
Staining of precursor RCC lessions 
 
IHC was performed on FFPE kidney tumor samples from patients with VHL (n=3) [REC 
16/WS/0039; and 2002/6486]. 3-µm serial sections mounted on Snowcoat X-tra slides 
(Surgipath, Richmond, IL) were dewaxed in xylene and rehydrated using graded ethanol washes. 
For antigen retrieval (CD10 and VCAM-1), sections were immersed in preheated DAKO target 
retrieval solution (DAKO) and treated for 90 seconds in a pressure cooker. Sections analysed 
contained both tumor and adjacent normal renal parenchyma acting as an internal control; in 
addition, substitution of the primary antibody with antibody diluent was used as a negative 
control. Antigen/antibody complexes were detected using the Envision system (DAKO) 
according to the manufacturer's instructions. Sections were counterstained with Gill’s 
hematoxylin for 30 seconds, dehydrated in graded ethanol washes, and mounted in DPX (Lamb, 
London, United Kingdom). Antibodies used were: CAIX (gift from S. Pastorekova, Institute of 
Virology, Bratislava, Slovak Republic), CD10 (clone: NCL-L-CD10-270, Novacastra) and 
VCAM-1 (clone: EPR5047, Abcam) 
 
Bulk DNA processing 
 
DNA was extracted from fresh frozen tissue. Peripheral blood DNA was used as a matched 
normal. 
Short insert (500bp) genomic libraries were constructed, flowcells prepared and 150 base 
pair paired-end sequencing clusters generated on the Illumina HiSeq X platform according to 
Illumina no-PCR library protocols (11). The average sequence coverage was 40X and 98X for 
renal and matched peripheral blood samples, respectively. 
 
Bulk DNA sequence alignment 
 
DNA sequencing reads were aligned to the GRCh 37d5 reference genome using the 
Burrows-Wheeler transform (BWA-MEM) (12). Sequencing depth at each base was assessed 
using Bedtools coverage v2.24.0.  
 
Substitution calling from bulk DNA 
 
Single base somatic substitutions were called using an in-house version of CaVEMan 
v1.11.2 (Cancer Variants through Expectation Maximization) (13). CaVEMan compares 
sequencing reads from tumor and matched normal samples and uses a naïve Bayesian model and 
expectation-maximization approach to calculate the probability of a somatic variant at each base 
(https://github.com/cancerit/CaVEMan). Small insertions and deletions (indels) were called 
using an in-house version of Pindel (v2.2.2; github.com/cancerit/cgpPindel). Point mutation 
variants were annotated using VAGrENT2 (14) according to ENSEMBL version 58. Post-
processing filters required that the following criteria were met to call a somatic substitution: 
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1. At least a third of the reads calling the variant had a base quality of 25 or higher.  
2. If coverage of the mutant allele was less than 8, at least one mutant allele was 
detected in the first 2/3 of the read.  
3. Less than 5% of the mutant alleles with base quality ≥ 15 were found in the matched 
normal.  
4. Bidirectional reads reporting the mutant allele. 
5. Not all mutant alleles reported in the second half of the read. 
6. Mean mapping quality of the mutant allele reads was ≥ 21. 
7. Mutation does not fall in a simple repeat or centromeric region. 
8. Position does not fall within a germline insertion or deletion. 
9. Variant is not reported by ≥ 3 reads in more than one percent of samples in a panel 
of approximately 400 unmatched normal samples. 
10. A minimum 2 reads in each direction reporting the mutant allele.   
11. At least 10-fold coverage at the mutant allele locus.  
12. Minimum variant allele fraction 5%.  
13. No insertion or deletion called within a read length (150bp) of the putative 
substitution.  
14. No soft-clipped reads reporting the mutant allele. 
15. Median BWA alignment score of the reads reporting the mutant allele ≥ 140.  
 
The following variants were flagged for additional inspection for potential artefacts, 
germline contamination or index-jumping event: 
 
16. Any mutant allele reported within 150bp of another variant. 
17. Mutant allele reported in >1% of the matched normal reads.  
 
Copy number detection in bulk DNA 
 
The ascatNGS algorithm (v4.0.1) (15) was used to estimate tumor purity and ploidy and to 
construct copy number profiles prior to running the Battenberg algorithm (v2.2.5) 
(github.com/cancerit/cgpBattenberg) to allow for tumor subclonality. 
 
Mapping and quantification of single cell RNA-seq 
 
Single cell RNA-seq data were quantified using the 10X software package cellranger 
(version 1.3.1) to map sequencing data to version 1.2.0 of the build of the GRCh38 reference 
genome supplied by 10X. 
 
This software produces a table of counts of unique molecular identifiers (UMIs) for each 
gene in roughly 1 million droplets per cell.  Next, we used the EmptyDrops package 
(https://github.com/TimothyTickle/hca-jamboree-cell-
identification/tree/master/src/poisson_model), which identifies droplets that have an expression 
profile that differs significantly from the expression profile of the unambiguously empty droplet 
with fewer than 100 UMIs (16).  We retained for further QC those droplets that either: 
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• Were identified by EmptyDrops as having expression significantly different from the 
background with 5% FDR. 
• Had total number of UMIs in excess of the minimum of: 
• 100,000. 
• The UMI cut-off identified by cellranger. 
• The UMI cut-off identified by the findKnee function in EmptyDrops. 
 
This method was used in preference to relying on the cellranger UMI cut-off alone (or the 
findKnee cut-off, which produces almost the same value for our data) as we found that there 
were a number of biologically plausible clusters of cells, which passed all our QC filters and 
were only identified by the EmptyDrops method. 
 
Quality control of single cell data 
 
To filter lower quality cells, we removed any cells that had greater than 20% expression 
originating from mitochondrial genes or expressed fewer than 200 distinct transcripts.  We used 
more liberal cut-offs than studies involving tissue that could be collected and prepared in ideal 
conditions (e.g., model organism studies such as (17)) in order to capture as broad a range of cell 
types as possible. 
 
Because our base line QC filters were fairly permissive, we further filtered our data by 
removing any clusters that had hemoglobin genes as one of its cluster defining genes.  This was 
done on the basis that such cells were either reticulocytes (and not of biological interest) or were 
heavily contaminated.  Finally, we removed clusters with biologically implausible combinations 
of markers that were suggestive of having captured doublets.  
 
In constructing a reference map of the mature and fetal kidneys and comparing this map to 
the tumor cells, we ignored any cluster that could not be unambiguously assigned using well 
established marker genes.  The full characterization and identification of marker genes for the all 
clusters (ambiguous and unambiguous) can be found in Fig. S2 to S8 and Table S2. 
 
Normalisation of single cell data 
 
Data was first normalized for sequencing depth by dividing by the total number of UMIs in 
each cell and then transformed to a log scale for each cell using the Seurat 
(http://satijalab.org/seurat/) NormalizeData function. That is, the transformed data, y, is given by: 
 
  
 
where x is the UMI count matrix with g indexing gene and c indexing the cell.  F is the 
Seurat "scale.factor" parameter (which we left at the default value of 10,000). 
 
ygc = log
 
1 + F
xgcP
g xgc
!
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Batch correction was performed using COMBAT (18) to regress out the variability 
introduced by individual 10X channels.  To prevent the batch correction from imputing 
expression from genes that have no expression, we forced all entries which were 0 before batch 
correction to remain 0 post batch correction.  Following this correction, we re-normalized the 
data such that it was consistent with being derived from an expression vector which sums to 1.  
That is, after re-normalization the data have the property that: 
 
 
 
where y is the final data matrix and cell. 
 
Feature selection and dimension reduction 
 
Following normalization, we identified genes with high variability using the Seurat 
FindVariableGenes function.  This function calculates the mean expression and dispersion for 
each gene, then groups genes into bins (of size 20) by their mean expression and identifies any 
gene for which the z-score calculated from the dispersion exceeds some cut-off.  We used a 
permissive cut-off of z=0.5 and mean expression in the range 0.0125 to 3 to ensure a large 
number of biologically variable genes were captured. 
 
The normalized data was scaled to have mean 0 and standard deviation 1 and principle 
component analysis was performed using the variable genes identified together with any gene 
that we identified as being potentially biologically interesting (regardless of its variability in the 
data). 
 
We then used the first 30 principle components (PCs) to construct a two-dimensional 
representation of the data using tSNE (19, 20) with perplexity 30 and using the Barnes-Hut 
approximation with opening angle theta=0.5 to speed up the calculation.  This representation was 
then used only to visualize the data.  
 
Cluster identification 
 
Clusters were identified using the community identification algorithm as implemented in 
the Seurat "FindClusters" algorithm (21).  We used the first 30 PCs as input to this method and 
set the resolution parameter to 1.  We chose this value of the resolution parameter as it produced 
a number of clusters that was large enough to capture most of the important biological variability 
but not so large as to make detailed manual scrutiny of each cluster impractical.  All other 
parameters were set to the function defaults. 
 
Allocation of cells to cellular compartments 
 
Cells were first split into tumor, normal and fetal based on the tissue of origin.  Within each 
of these three groups, cells were initially assigned to either immune or epithelial and vascular 
based on the average PTPRC (CD45) expression within each cluster.  Clusters of cells were then 
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annotated within each of these compartments and clusters of cells that were deemed to be 
misplaced based on marker gene expression were moved to the correct compartment. 
 
In the case of the normal mature kidney, we found that the majority of the cells (80%) were 
proximal tubular cells of indistinct type.  In order to obtain sufficient detail to identify all cell 
types, we created a further sub-compartment that excluded this mass of proximal tubular cells 
(see Fig. S2).  This sub-compartment (Fig. 1, Fig. S2) allowed us to capture the full diversity of 
normal cell types present in the normal epithelium and vasculature.  
 
Annotation of clusters 
 
Annotation of clusters to cell types was done by manual inspection of the genes defining 
each cluster and comparison to the literature.  To identify which genes were most important in 
defining each cluster we ranked genes by an adaption of the "tf-idf" metric widely used in natural 
language processing (22).  From this ranked list, we inspected the minimum of 100 or all those 
genes for which the genes presence was enriched within a cluster relative to all other clusters in 
its cellular compartment (e.g., cluster 7 in the tumor immune map versus all cells in the tumor 
immune map not in cluster 7) by a hypergeometric test with a 0.01 p-value cut-off after multiple 
hypothesis correction. 
 
The purpose of the tf-idf ranking was to provide a computationally efficient way of 
identifying all those genes with expression specific to a cluster.  The tf-idf value was calculated 
for each gene as, 
 
  
 
where f is the fraction of cells in cluster c with non-zero expression of gene g and F is the 
fraction of cells in the entire map expressing gene g.  Note that the p-values derived from the 
hypergeometric test are mathematically equivalent to calculating p-values by permuting the 
labels and recalculating the tf-idf score an infinite number of times. 
 
Pseudo-time analysis 
 
To place cells onto pseudo-time trajectories, cells were re-processed using the monocle R 
package (23) by excluding all genes expressed in fewer than 3 cells and normalizing for library 
size using the "estimateSizeFactors" function. 
 
Following this, negative binomial over-dispersion was estimated for each gene using the 
"estimateDispersions" function.  Dimension reduction was then performed using the DDRTree 
method on genes selected to have a mean expression value > 0.1 and variance greater than the 
empirical dispersion (the best fit mean-dispersion trend-line). 
 
Finally, cells were placed onto a pseudo-time trajectory using the "orderCells" function 
(24). 
 
Identification of genes differentially expressed along pseudo-time trajectory 
 fgc log(Fg)
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The pseudo-time trajectory inferred from the cells comprising the mesenchymal population 
of the developing nephron had minimal branching structure and so we considered only the 
distance from the root node (representing the cap mesenchyme) for the purpose of identifying 
changes in expression pattern. 
 
To identify genes which changed steadily along the identified trajectory we performed a 
likelihood ratio test for a negative binomial model with and without a term given by spline 
smoothing of the pseudo-time using the "differentialGeneTest" function.  We restricted our test 
to the 1691 transcription factors identified by the AnimalTFDB project (25, 26) and identified all 
genes that were significant at a strict 0.01 p-value cut-off after multiple hypothesis correction. 
 
For trajectories that exhibited significant branching structure, where testing for differences 
along a linearized pseudo-time axis would not be valid, we instead tested for differences along 
each branch relative to the other branch and the root.  These statistical tests were performed 
using the BEAM algorithm implemented in monocle and we retained any transcription factor 
(from the same list as above) with a p-value less than 0.01 after multiple hypothesis correction. 
 
Differential expression between ureteric bud and cap mesenchyme/primitive vesicle 
 
To identify genes differentially expressed between ureteric bud and cap 
mesenchyme/primitive vesicle we labelled all cells belonging to these populations as either 
ureteric bud (UB) or cap mesenchyme/primitive vesicle (CM/PV).  The same cut-offs and test 
(negative binomial model based likelihood ratio test) as was used to identify transcription factors 
differentially expressed along pseudotime were used to compare a model with and without this 
label as a covariate and to identify differentially expressed transcription factors distinguishing 
these two populations. 
 
Cell type similarity inference 
 
To measure the similarity of tumor cells to either normal mature kidney cells or fetal cells, 
we trained a logistic regression model using elastic net regularization on the cellular identities 
defined by the clusters in normal mature and fetal epithelial and vascular compartments.  In 
training this model we set alpha=0.99 to produce strong regularization but to prevent the 
exclusion of strongly co-linear genes.  
 
To obtain regression coefficients specific to each cluster in our training data we fit a series 
of N binomial logistic regression models, where N is the number of clusters in the training data 
(i.e., one-versus-rest binomial logistic regression).  To prevent the observed frequencies of cells 
(which we do not expect to accurately reflect the true abundances in situ) from biasing the 
regression coefficients we use an offset for each model given by, 
 
 
 
where f is the fraction of cells in the cluster being trained.  
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In each case, we performed 10-fold cross validation and selected the regularization co-
efficient, lambda, to be as large as possible (i.e., as few non-zero coefficients as possible) such 
that the cross validated accuracy was within 1 standard deviation of the minimum. 
 
These models were then used to calculate a predicted similarity to each of the fetal and 
normal clusters for each cell in the tumor map.  In calculating the predicted values, an offset of 0 
was used.  Softmax normalization was not used to allow for the possibility that tumor cells do 
not resemble any of the fetal or normal cells in the training set.  Predicted logits were then 
averaged within each tumor cluster and converted to probabilities for visualization. 
 
This approach was implemented using the "glmnet" R package (27) . 
 
Identification of tissue specific genes 
 
To identify genes that were specific to one cell type and no other in the kidney (e.g., that 
NMU is only expressed in ureteric bud in the fetal kidney), we utilized a series of cut-offs on 
fraction of cells expressing a given gene of interest.  Specifically, we identified all genes for 
which the percentage of cells expressing a gene in the target cluster (the cluster the gene is 
specific for) was 20% higher than all other clusters and that no other cluster had more than 10% 
of cells expressing this gene.  To avoid intermediate populations in the developing nephron 
excluding useful genes, we required for this population only that a candidate gene be expressed 
most frequently in the target population and that no other non-nephrogenesis cluster had more 
than 10% of cells expressing the candidate gene. 
 
Differential expression of marker genes in bulk data 
 
To measure the expression of cell specific markers in bulk TCGA and TARGET data, a 
table of counts was retrieved from TCGA (28, 29) and TARGET (30, 31) using the R 
TCGAbiolinks package (32). We filtered these samples to retain only primary tumors from 
Wilms, malignant Rhabdoid tumors (MRT), ccRCC, pRCC, chromophobe RCC (chrRCC) or 
normal tissue biopsies.  These counts were then normalized to produce log (TPM) for each 
gene/sample pair for visualization.  
 
To determine differentially expressed transcripts between different groupings of tumor and 
normal, we used a Mann-Whitney test to compare the distribution of log2 transformed TPM 
values between the two groups and kept genes with a p-value less than 0.01.  For a gene to be 
considered differentially expressed, we further required that the median log2(TPM) values of the 
two distributions differ by at least 1. 
 
Genotyping of tumor cells 
 
Genomic variation present in individual cells is captured by 10X single cell RNA-seq.  
However, the regions of the genome which are covered is limited by the fact that only highly 
expressed genes are captured, and within the genes that are captured the sequence is enriched for 
3' mRNA.  To overcome these coverage limitations and detect genomic variation in single cells 
we aggregated information across as large a genomic region as possible within each cell. 
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Rather than attempt to detect genomic changes de novo, we utilized bulk sequencing of 
tumor DNA and peripheral blood to identify the dominant clonal genomic changes present in 
each cancer.  In the case of single base substitutions, we considered only those changes with a 
VAF of at least 20% in the tumor to enrich for clonal substitutions.  We then calculated a global 
"Mutant Allele Frequency" (MAF) for each cell by aggregating the number of UMIs supporting 
the mutant and wild type alleles across all substitutions in the genome.  For each molecule we 
determined the allele by taking the consensus base across all the reads covering that base with 
the same UMI.  If there was no consensus call, the UMI was not included in the calculation of 
the MAF.  We excluded any variant that did not fall within a gene body. 
 
To detect the presence of clonal copy number (CN) changes, we considered only clonal 
losses of heterozygosity (LOH), except for the pRCC tumor where no LOH events could be 
found.  In the case of the pRCC, we instead used the 2-to-1 gains on chromosomes 3,12, and 17.  
In each patient we identified all SNPs heterozygous in the peripheral blood in the regions where 
the clonal CN changes occur using a B allele frequency cut-off of 0.4 to 0.6.  We then phased 
these SNPs by designating the allele with the highest B allele frequency in the tumor (i.e., the 
allele on the gained or retained allele) as the "Major" allele.  We considered only those alleles for 
which the B allele frequency in the tumor was significantly different from 50/50 as measured by 
a binomial test followed by multiple hypothesis correction. 
 
For all samples, we used a corrected p-value cut-off of 0.1, except for RCC1 where we used 
a cut-off of 0.5.  We elected to use a weaker cut-off for RCC1 as it had a much higher level of 
genomic contamination and the stronger cut-off left us with too few informative SNPs to call CN 
changes.  The effect of using a weaker cut-off is to mis-phase a larger number of SNPs, which 
pulls the signal in the single cell data away from the expected allelic ratio, but does not remove it 
entirely. 
 
Next, we calculated the frequency of the major allele across all informative SNPs from the 
single cell data on a cell-by-cell basis.  In each case we aggregated the information across all 
informative SNPs in the genome to calculate one allele frequency for each cell.  To prevent allele 
specific expression cofounding our signal, we excluded any gene that showed consistent 
expression of one allele across all cell types (i.e., including those from normal tissue we expect 
to be genotypically normal) as measured by an allele frequency greater than 0.7 (or less than 0.3) 
and a corrected p-value from a binomial test of less than 0.05. 
 
These two approaches provided two independent methods of measuring the presence of 
clonal genomic variations in individual cells.  To provide further evidence of the degree to which 
clusters of cells identified by their single cell transcriptomes carried the clonal tumor genotype, 
we aggregated counts across groups of cells to calculate the mutation and CN allele frequency 
for each cluster of cells (Fig S11-S14)  
 
Comparison of fetal and Wilm's tumor TF program 
 
To test if the transcription factors (TFs) that define the different Wilm's tumor cell types 
overlap significantly with the transcription factors that define normal nephron development we 
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extracted all TFs that were significantly altered along the pseudo-time trajectory in fetal nephron 
development or along the branched trajectory defined by Wilm's tumor cells.  A hypergeometric 
test was then performed to compare the null hypothesis of no enrichment of the fetal group of 
TFs for the Wilm's TFs against a background of 1691 TFs (25, 26). 
 
Doublet mitigation strategy 
 
Droplet-based technologies are known to produce “doublets”, where two cells are captured 
within a single droplet.  At the concentrations of cells used in our experiment, we expect the 
stochastic doublet rate to be very low (~1%) (33).  However, we cannot exclude the possibility of 
“biological doublets”, where cells have a propensity to be captured together due to mutual 
affinity or failure to dissociate.  At present, we know of no informatic tools to reliably remove 
such doublets.  We controlled for this problem by removing clusters of cells with a 
transcriptomic signature of multiple cell types, but cannot exclude the possibility that we 
discarded interesting populations of cells in the process. 
 
Limitations of single cell assay 
 
The aim of this experiment was to provide an unbiased survey of the cell types comprising 
human kidney (in health and malignancy) at a molecular level.  For this reason, we chose to use 
an assay that maximised the number of cells we were able to profile (droplet-based sequencing).  
The trade-off of this approach is that in each cell, a fraction of the transcriptome is not captured.  
We believe this approach is justified for a broad survey such as ours as most cell types can be 
unambiguously distinguished by the presence of only a handful of genes (we were able to 
distinguish all parts of the nephron using ~30 genes).  To further compensate for this limitation, 
we have limited ourselves to making statements about groups of cells. By averaging across the 
cell-to-cell transcriptomic stochasticity, a more complete picture of each cell type’s 
transcriptome is obtained. However, we cannot exclude the possibility that an assay with greater 
transcriptomic coverage would allow for greater segregation of the cell types identified here. 
 
Although at present our approach probably represents the “gold standard” for surveying 
tissues, it is likely that systematic biases against capturing certain cell types exist. For example, 
we found no convincing fibroblast population in mature kidneys, whilst in ureter and fetal 
kidneys these were consistently seen. This may be due to the rarity of fibroblasts in mature 
kidney or due to technical biases preventing isolation of fibroblasts from mature tissue. 
Similarly, WT1 positive podocytes were more prevalent in kidneys of the two youngest children 
in our data, leading us to hypothesise that WT1 podocyte abundance decreases with age.  
However, immunohistochemical staining showed this population to be present across a range of 
ages. 
 
Data availability 
 
Raw sequencing data have been deposited in the European Genome-phenome Archive 
(EGA) under study IDs EGAS00001002171, EGAS00001002486, EGAS00001002325, 
EGAS00001002553 and EGAS00001002534.  Sample specific identifiers can be found in Table 
13 
S6.  The raw table of counts for all droplets identified as potentially containing cells (125,139) is 
included as a supplementary data file Data S1. 
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Figure S1. Overview of droplet quality control and cell allocation to compartments 
Flow chart indicating how many candidate droplets are removed by quality control and how the 
resulting 72,501 cells are divided into different compartments.  The bar plot on the right shows 
the fraction of droplets remaining after each QC step for each biopsy in our experiment. 
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Figure S2. Full characterization of non-immune mature kidney cells 
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The left panel shows a tSNE representation of the 8,707 cells in the normal mature kidney map (see Fig. S1), with clusters labeled 
(with aliases in brackets where applicable), colored and emphasized with density contours.  The aliases represent the following cell 
types: “G” for Glomerulus, “PT1” for convoluted proximal tubular, “PT2” and “PT3” for straight and convoluted proximal tubular, 
“H” for loop of Henle, “D” for distal tubules, “C1” for Type B collecting duct, “C2” for Type A collecting duct, “P” for renal pelvic 
epithelium, “U1” for basal and intermediate ureter, “U2” for mixed ureter, “U3” and “U4” for superficial cells, “F” for fibroblasts, 
“M” for myofibroblasts, “GE” for glomerular endothelium, “DV” for ascending vasa recta and “AV1” and “AV2” for ascending vasa 
recta. 
The right panel shows the expression of the top 5 most specific marker genes for each cluster (see Methods) and the expression of 
canonical markers curated from the literature (see Table S3).  Within each group of genes, rows are hierarchically clustered and 
expression (fraction of cells expressing the gene in each cluster) is row normalized to have mean 0 and standard deviation 1.  Cluster 
are organized from proximal to distal as in Fig. 1C,D with ambiguous clusters on the far right.  Genes that are identified as being 
markers of different types of kidney cell in the literature are marked with a “*” in the row labels on the right. 
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Figure S3. Full characterization of immune cells in the mature kidney 
The left panel shows a tSNE representation of the 4,796 immune cells in the normal mature kidney map (see Fig. S1), with clusters 
labeled (with aliases in brackets where applicable), colored and emphasized with density contours.  The aliases represent the following 
cell types: “NK1” and “NK2” for natural killer cell, “NKT1” and “NKT” for natural killer T-cell, “Th” for T helper cell, “MNP1-3” 
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for Mononuclear phagocyte, “8T” for CD8+ T-cell, “NP” for neutrophil, “B” for B-cell, “MST” for Mast cell and “PDC” for 
plastmacytoid dendritic cell. 
The right panel shows the expression of the top 5 most specific marker genes for each cluster (see Methods) and the expression of 
canonical markers curated from the literature (see Table S3).  Within each group of genes, rows are hierarchically clustered and 
expression (fraction of cells expressing the gene in each cluster) is row normalized to have mean 0 and standard deviation 1.  Genes 
that are identified as being markers of different types of kidney cell in the literature are marked with a “*” in the row labels on the 
right. 
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Figure S4. Full characterization of all non-immune mature kidney cells 
 21 
The left panel shows a tSNE representation of the 37,951 non-immune cells in the normal mature kidney map (see Fig. S1), with 
clusters labeled (with aliases in brackets where applicable), colored and emphasized with density contours.  The tSNE map is 
annotated to indicate which clusters of cells are retained for the reference map of the non-immune mature kidney. 
The right panel shows the expression of the top 5 most specific marker genes for each cluster (see Methods) and the expression of 
canonical markers curated from the literature (see Table S3).  Within each group of genes, rows are hierarchically clustered and 
expression (fraction of cells expressing the gene in each cluster) is row normalized to have mean 0 and standard deviation 1.  Genes 
that are identified as being markers of different types of kidney cell in the literature are marked with a “*” in the row labels on the 
right. 
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Figure S5. Full characterization of non-immune fetal kidney cells 
The left panel shows a tSNE representation of the 4,858 non-immune cells of the normal fetal kidney map (see Fig. S1), with clusters 
labeled (with aliases in brackets where applicable), colored and emphasized with density contours.  The aliases represent the following 
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cell types: “fE” for endothelium, “fF” for fibroblasts, “fM” for myofibroblasts, “fGA” for ganglia, “UB” for ureteric bud, “CM” for 
cap mesenchyme and “PV” for primitive vesicle. 
The right panel shows the expression of the top 5 most specific marker genes for each cluster (see Methods) and the expression of 
canonical markers curated from the literature (see Table S3).  Within each group of genes, rows are hierarchically clustered and 
expression (fraction of cells expressing the gene in each cluster) is row normalized to have mean 0 and standard deviation 1.  Genes 
that are identified as being markers of different types of kidney cell in the literature are marked with a “*” in the row labels on the 
right. 
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Figure S6. – Full characterization of immune cells in the fetal kidney 
The left panel shows a tSNE representation of the 742 immune cells in the normal mature kidney map (see Fig. S1), with clusters 
labeled (with aliases in brackets where applicable), colored and emphasized with density contours.  The aliases represent the following 
cell types: “fMNP1” and “fMNP2” for mononuclear phagocytes, “fNKT” for natural killer T cells and “fMk” for megakaryocytes. 
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The right panel shows the expression of the top 5 most specific marker genes for each cluster (see Methods) and the expression of 
canonical markers curated from the literature (see Table S3).  Within each group of genes, rows are hierarchically clustered and 
expression (fraction of cells expressing the gene in each cluster) is row normalized to have mean 0 and standard deviation 1. Genes 
that are identified as being markers of different types of kidney cell in the literature are marked with a “*” in the row labels on the 
right. 
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Supplementary Figure S7. Full characterization of non-immune kidney tumor cells 
The left panel shows a tSNE representation of the 6,333 non-immune cellsfrom all kidney tumor biopsies (see Fig. S1), with clusters 
labeled (with aliases in brackets where applicable), colored and emphasized with density contours.  The aliases represent the following 
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cell types: “tE1-3” for endothelium, “cR1-7” for ccRCC, “W1-3” for Wilms’ tumor, “tM1” and “tM2” for myofibroblasts, “WF” for 
Wilms’ tumor and fibroblasts and “pR” for ppRCC. 
The right panel shows the expression of the top 5 most specific marker genes for each cluster (see Methods) and the expression of 
canonical markers curated from the literature (see Table S3).  Within each group of genes, rows are hierarchically clustered and 
expression (fraction of cells expressing the gene in each cluster) is row normalized to have mean 0 and standard deviation 1.  Genes 
that are identified as being markers of different types of kidney cell in the literature are marked with a “*” in the row labels on the 
right. 
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Supplementary Figure S8. Full characterization of kidney tumor immune cells 
The left panel shows a tSNE representation of the 17,821 immune cells from all kidney tumor biopsies (see Fig. S1), with clusters 
labeled (with aliases in brackets where applicable), colored and emphasized with density contours.  The aliases represent the following 
cell types: “tTh1-2” for T helper cells, “t8T1-3” for CD8+ T-cells, “tMNP1-5” for mononuclear phagocytes, “tTr” for T regulatory 
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cell, “tNKT” for natural killer T-cells, “tNK1-3” for natural killer cells, “tT” for proliferating T-cells, “tMST1-2” for mast cells, 
“tPDC” for plasmacytoid dendritic cells, “tP” for plasma cell, “tE” for erythroblast, “tB” for B-cell and “tNP” for neutrophils. 
The right panel shows the expression of the top 5 most specific marker genes for each cluster (see Methods) and the expression of 
canonical markers curated from the literature (see Table S3).  Within each group of genes, rows are hierarchically clustered and 
expression (fraction of cells expressing the gene in each cluster) is row normalized to have mean 0 and standard deviation 1.  Genes 
that are identified in the literature as being markers of different types of kidney cell in the literature are marked with a “*” in the row 
labels on the right. 
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Supplementary Figure S9. Copy number profiles of tumors from bulk DNA 
Copy number profiles for each tumor as determined by Battenberg on match tumor/normal 
whole genome sequencing (see Methods).  The red line indicates the total copy number and the 
blue line the copy number of the minor allele. 
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Supplementary Figure S10. Overview of the genotyping of individual cells using single cell 
RNA-seq data 
A plot summarizing the evidence supporting the presence in clusters of single cells of the 
somatic genomic changes (CN changes and single nucleotide variants) identified as clonally 
present in each tumor using bulk DNA (see Methods).  Each column shows a different cellular 
compartment (i.e., a different grouping of cells as shown in Fig. S1).  Within each column, each 
entry on the x-axis represents an individual cluster.  Within each cluster, the cells derived from 
each of the different tumor samples are compared to the somatic genotype for their 
corresponding tumor, which is what each row represents.  For example, looking in the second 
column (Normal Immune), at the third row (RCC2) at the first entry (N0) summarizes the 
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evidence for those cells in cluster N0 in the normal immune map (Fig. S3) that are taken from 
the normal biopsy from patient RCC2 having the clonal CN change and single nucleotide 
variants found in the DNA of the tumor biopsy taken from RCC2. 
For each cluster/sample combination, two points are shown: a triangle representing substitutions 
and a circle representing CN.  For the substitutions, the mutant allele frequency (MAF) is 
calculated as the total fraction of reads supporting the mutant allele derived from the DNA, 
summed across all substitutions in the genome and all cells in this grouping.  If the cells in this 
cluster are not tumor cells, we expect a MAF of close to 0.  For the CN, the MAF is calculated as 
the fraction of reads supporting the major allele, which is defined to be the allele of heterozygous 
SNPs that falls on the chromosome with the highest copy number (see Methods).  If the cells in 
this cluster are not tumor cells, we expect a MAF of close to 0.5.  Error bars showing the 95% 
confidence interval on the estimate of the MAF for each point are shown and points that are 
significantly different from the expected MAF (0 for substitutions, 0.5 for CN; q<0.01) are 
colored green. Clusters where one or both of the symbols are missing indicate that there were no 
cells with informative reads for that particular combination of cluster, tumor genotype and 
variant type (SNV or CN).   
Clusters of cells that contain the tumor genotype can be clearly identified in the clusters of single 
cells in the tumor epithelial and vascular compartment.  There is no cluster outside this 
compartment where the CN and SNV data both support the tumor genotype being present. 
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Supplementary Figure S11. – CN genotyping of every non-immune tumor cell 
 
Each point in this map represents a tumor cell (see Fig. S7) and is colored by the sample it was 
generated from.  For each cell, an allele frequency is calculated by averaging across the allele 
with the largest CN in the bulk DNA data for the relevant sample.  The size of the point indicates 
the number of informative reads that are available for this cell and the shape indicates if the 
deviation of the allele frequency from 0.5 (the expected value if the cell is CN neutral) is 
significant (FDR < 0.01; binomial test).  The shading of each cell indicates the observed allele 
frequency, with any allele frequency less than 0.5 shown in white.  Cells for which no 
informative reads were available are plotted as a single dot.  As an example, a square with a red 
outline indicates a cell from the pRCC sample for which the allele frequency significantly 
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exceeds 0.5.  In this case the allele frequency is the sum across SNPs belonging to the allele with 
the largest number of copies in the clonal CN change identified in the bulk DNA from the pRCC 
sample.  The shading indicates the exact value of this allele frequency and the size of the dot 
indicates how many reads it is based on, with larger dots indicating more reads on a log2 scale. 
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Supplementary Figure S12. CN genotyping of every immune tumor cell 
As in Fig. S11 except the genotyping of CN of tumor immune cells (Fig. S8) is shown as a 
negative control. 
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Supplementary Figure S13. Substitution genotyping of every non-immune tumor cell 
As in Fig. S11 except here the allele frequency represents the fraction of reads supporting the 
mutant allele at all single nucleotide variants identified in the bulk DNA.  As the expected allele 
frequency for a cell with the wild type genotype is 0, squares show those cells for which the 
allele frequency significantly exceeds 0 and the shading covers all values of the MAF rather than 
being truncated at 0.5 as was done in Fig. S11. 
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Supplementary Figure S14. – Substitution genotyping of every immune tumor cell 
As in Fig. S11 except the genotyping of substitutions of tumor immune cells (Fig. S8) is shown 
as a negative control.  
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Supplementary Figure S15. – Expression of key genes in all bulk RNA-seq data for studied 
tumor types 
A heatmap showing the expression of the key markers of the PT1 population of proximal tubular 
cells (Fig. 1C; Fig. S2) and of the ureteric bud and primitive vesicle (Fig. 2C; Fig. S5).  
Specifically, PT1 cells are SLC17A3+, SLC7A13- and VCAM1+, UB cells are NMU+ and PV 
cells are RSPO1+.  The color scheme shows the log2(TPM) expression of each sample (row) 
where rows have been split into the three cancer types and normal and then heirachically 
clustered. 
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Figure S16. VCAM1 staining in tumors of patients predisposed to clear cell renal cell 
carcinoma.  
Tumor sections of a ccRCC from a patient with a pathogenic germline mutation in the VHL gene 
are shown to demonstrate that VCAM1, a PT1 marker, is expressed by cancer cells. 
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Supplementary Figure S17. Expression of markers of tumor associated genes in bulk RNA-
seq 
Boxplots showing the expression of key markers of myofibroblasts (first row), vascular 
endothelium (second row) and fibroblasts (third row) for bulk RNA-seq data from normal 
kidney, Wilms tumor, ccRCC and pRCC respectively (see Methods). 
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Supplementary Figure S18. – Full characterization of kidney tumor immune cells 
(A) VEGF signaling derived from single cell data. Expression of VEGFA/VEGFC, its receptors 
(FLT1, FLT4, and KDR), and ACKR1 in clusters of ccRCC, cancer endothelium and 
 43 
macrophages. Circles represent clusters, bar plots fractional expression and arrows 
receptor/ligand interactions or the facilitation of migration (ACKR1). 
(B) Validation of VEGFA bearing macrophages by flow cytometry. We gated on live, CD45+ 
cells (following exclusion of doublets), CD19 and CD3 negative cell within this gate were then 
analyzed for their expression of MHCII and CD68 to identify macrophages. 
(C) CD68+ VEGFA+ cells. Representative histogram showing VEGFA staining in tumor 
macrophages (Live/lin-negative, CD68/MHCII+ cells, red line), in CD45 negative cells (blue 
line). Isotype control staining shown in grey filled histogram. 
(D) Confocal microscopy showing co-localization of CD68, MHCII, and VEGFA. 
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Supplementary Figure S19. Comparison of dissociation protocols 
Flow cytometric assessment of mechanical dissociation alone or in combination with liberase 
shows that some cell populations, here CD45+ cells, are missed when mechanical dissociation is 
used alone. The experimental protocol is described in Methods. 
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Donor (study ID) Experiment Age Normal kidney Renal pelvis Ureter Tumor Tumor type 
Foetus1 Foetus16 8 PCW 1 - - - - 
Foetus2 Foetus17 9 PCW 1 - - - - 
Child1 Wilms1 4 years 2 months 2 (1 Nephrogenic Rest) - - 1 Wilms' 
Child2 Wilms2 8 months 2 1 1 1 Wilms' 
Child3 Wilms3 2 years 6 months 2 1 1 1 Wilms' 
Adolescent Declined_transplant 12 years 6 (2 kidneys) - - - - 
Adult1 PapRCC 70 1 - - 1 Papillary cell carcinoma 
Adult2 RCC1 67 2 - 1 2 Clear cell carcinoma 
Adult3 RCC2 63 1 - - 2 Clear cell carcinoma 
Adult4 VHL_RCC 49 2 - - 1 Clear cell carcinoma 
Adult5 RCC3 72 2 - 1 1 - 
Table S1. Patient manifest 
Clinical features of the data.  Age for fetal samples is given in post conception weeks (34).  Numbers give the number of biopsies 
taken from each sample. 
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Please note that this table has been uploaded as a separate file 
named SupplementaryTables.xlsx and can be found on the 
sheet labeled “TableS2 – Cluster info” or in TableS2.xlsx 
Table S2. Summary of clusters 
Annotation and other information about clusters of cells.  Each cluster is given a unique Cluster 
ID and optionally a more informative alias.  The annotation of each cluster is giving in 
increasing level of detail in the columns “Cell_type1”, “Cell_type2” and “Cell_type3”.  The 
column “Positive_marker_mRNA” gives the names of those genes that were used to assign a cell 
type to this cluster.  The genotype column indicates if the majority of cells in this cluster carry 
the genotype of tumor, normal or nephrogenic rest cells identified from bulk DNA sequencing.  
Those clusters which could not be unambiguously identified as one cell type were labelled as 
“Junk”. 
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Gene Marker_of Reference 
MET pRCC (29) 
SIX2 CapMesenchyme (35, 36) 
CITED1 CapMesenchyme (35, 36) 
PAX2 CapMesenchyme (35, 36) 
SIX1 CapMesenchyme (35, 36) 
CA9 ccRCC (28) 
ATP6V0D2 Collecting_duct (37-39) 
CLCNKB Collecting_duct (37-39) 
SLC26A4 Collecting_duct_A (37-39) 
SLC4A1 Collecting_duct_B (37-39) 
AVPR2 Distal (37-39) 
SLC8A1 Distal (37-39) 
KCNJ1 Distal (37-39) 
CLDN8 Distal_collecting (37-39) 
SFRP2 Fibroblast (40, 41) 
EMILIN1 Fibroblast (42) 
MMP2 Fibroblast (42) 
CLDN5 Glom_vascular (37-39) 
SEMA3G Glom_vascular (37-39) 
AQP1 Glom_vascular (37-39) 
PTPRO Glomerulus (37-39) 
PODXL Glomerulus (37-39) 
WT1 Glomerulus (37-39) 
PTPRO Glomerulus_PrimitiveVesicle (37-39) 
PODXL Glomerulus_PrimitiveVesicle (37-39) 
WT1 Glomerulus_PrimitiveVesicle (37-39) 
CLDN16 Henle_ascending (37-39) 
SLC12A1 Henle_descending (37-39) 
PDGFRB Myofibroblasts (43) 
ACTA2 Myofibroblasts (43) 
NDUFA4L2 ccRCC (44) 
KRT23 Pelvic (37-39) 
SAA2 Pelvic (37-39) 
TP63 Pelvic_ureter (45) 
PVRL4 Pelvic_ureter (45) 
KRT5 Pelvic_ureter (45) 
UPK1B Pelvic_ureter (45) 
UPK1A Pelvic_ureter (45) 
DHRS2 Pelvic_ureter (45) 
S100P Pelvic_ureter (45) 
AQP2 Principal_cells (38, 39) 
SLC13A3 Proximal (38, 39) 
SLC34A1 Proximal (38, 39) 
SLC17A3 Proximal_convoluted (38, 39) 
SLC22A8 Proximal_convoluted (38, 39) 
SLC7A13 Proximal_straight (38, 39) 
SLC16A9 Proximal_straight (38, 39) 
SLC22A7 Proximal_straight (38, 39) 
HNF1B UretericBud (35, 36) 
RET UretericBud (35, 36) 
GATA3 UretericBud (35, 36) 
ELF3 UretericBud (35, 36) 
POU3F3 UretericBud (35, 36) 
TFCP2L1 UretericBud (35, 36) 
CDH16 UretericBud (35, 36) 
PLVAP Vascular (46) 
SLC14A1 Vascular (46) 
VCAM1 Vascular (46) 
KDR Vascular (46) 
PTPRB Vascular (47) 
PECAM1 Vascular (46) 
Table S3. Markers curated from the literature 
Genes used as markers of different cell types and the reference that justifies their use. 
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Please note that this table has been uploaded as a separate file 
named SupplementaryTables.xlsx and can be found on the 
sheet labeled “TableS4 –Algorithmic markers” or in 
TableS4.xlsx 
Table S4. Algorithmically identified marker genes of each cluster 
Genes specific to different clusters of cells and the evidence for their specificity.  Genes listed 
here have a FDR <0.05 from a hypergeometric test (see Methods) or are one of the 7 key genes 
that are listed for all clusters.  The column, “isKeyGene” indicates if a gene is a key gene that is 
always listed or listed because it is statistically significant.  The fraction of cells expressing a 
gene (prefix “geneFrequency”) and average normalized expression (prefix “geneExpression”) 
within each cluster, outside of each cluster and across all cells is given.  Within each cluster, 
genes are sorted by their tf-idf value (see Methods). The unique cluster ID is given in the 
“Cluster” column (see Table S2. for aliases). 
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Please note that this table has been uploaded as a separate file 
named SupplementaryTables.xlsx and can be found on the 
sheet labeled “TableS5 – Nephrogenesis TFs” or in 
TableS5.xlsx 
Table S5. Transcription factors important to nephrogenesis 
Transcription factors that are differentially expressed between UB and CM/PV or change 
significantly along the pseudotime axis joining CM and PV cells (Fig. 2D).  The p-values for 
these two tests is given along with the average expression of each gene in each of the three 
populations (UB, CM, and PV). 
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Please note that this table has been uploaded as a separate file 
named SupplementaryTables.xlsx and can be found on the 
sheet labeled “TableS6 – Sample manifest” or in TableS6.xlsx 
Table S6. Sample manifest 
Manifest describing each of the 10X channels processed.  There is a one-to-one correspondence 
between 10X channels and SangerID.  The column “Label” gives a compact summary of each 
channel’s meta-data in the format: 
<Experiment>_<Organ>_<Location>_<SortUsed>_<BioRepNo>_<TechRepNo> 
All other columns are self explanatory except for “BulkID” which gives the ID of the bulk DNA 
samples that correspond to this channel of data. 
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Chr Start End TotalCN MinorCN Experiment PD_ID 
2 199481900 242985493 1 0 RCC1 PD37104a 
3 60197 84808933 1 0 RCC1 PD37104a 
3 84809350 197846280 2 0 RCC1 PD37104a 
9 209134 141068960 1 0 RCC1 PD37104a 
13 19455253 65486222 1 0 RCC1 PD37104a 
14 20433516 107283886 1 0 RCC1 PD37104a 
2 211334242 242985493 1 0 RCC2 PD37228c 
3 65982 90362964 1 0 RCC2 PD37228c 
3 93505756 197811124 3 1 PapRCC PD35918h 
12 188285 133812333 3 1 PapRCC PD35918h 
17 9034 79998834 3 1 PapRCC PD35918h 
2 55984 242985493 3 1 VHL_RCC PD36793a 
3 60596 83348972 1 0 VHL_RCC PD36793a 
3 83352258 197606877 3 1 VHL_RCC PD36793a 
5 850203 107560911 3 1 VHL_RCC PD36793a 
5 107562191 180687907 5 2 VHL_RCC PD36793a 
7 115401 159122682 3 1 VHL_RCC PD36793a 
9 203937 141068960 3 1 VHL_RCC PD36793a 
10 266373 135235890 3 1 VHL_RCC PD36793a 
11 196944 134944142 3 1 VHL_RCC PD36793a 
12 188285 133839356 3 1 VHL_RCC PD36793a 
13 19455957 114999838 3 1 VHL_RCC PD36793a 
15 20021973 102431166 3 1 VHL_RCC PD36793a 
16 84170 53627229 3 1 VHL_RCC PD36793a 
16 53628412 89997381 2 0 VHL_RCC PD36793a 
17 27074565 79998834 3 1 VHL_RCC PD36793a 
18 125371 78017073 2 0 VHL_RCC PD36793a 
19 226776 59097308 3 1 VHL_RCC PD36793a 
20 20000786 62954871 3 1 VHL_RCC PD36793a 
21 15345102 48101335 3 1 VHL_RCC PD36793a 
11 78383801 134937738 1 0 Wilms1 PD36165d 
12 203339 133839356 3 1 Wilms1 PD36165d 
16 35272667 89973832 1 0 Wilms1 PD36165d 
2 96057011 242852391 2 0 Wilms2 PD37272a 
16 86084 89998157 4 1 Wilms3 PD37276a 
16 32156537 33767707 3 1 Wilms1NR PD36165e 
Table S7. Clonal copy number changes in tumor DNA 
Table of copy number changes identified in bulk DNA for each of the tumor samples in our 
experiment 
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Please note that this table has been uploaded as a separate file 
named SupplementaryTables.xlsx and can be found on the 
sheet labeled “TableS8 – Markers of UB and PV” or in 
TableS8.xlsx 
Table S8. Genes globally specific to ureteric bud or primitive vesicle 
Statistics summarizing how specific each gene is to the ureteric bud or primitive vesicle cluster 
in the fetal single cell data (“MarkerClusterFrequency” column), relative to other clusters in the 
fetal nephron (“MaxFetalNephFrequencyExcluingMarker” column) and all other non-tumor 
single cell clusters (“MaxOutOfClusterFrequency” column).  Genes that meet the criteria for 
being globally specific markers of the UB or PV defined in Methods are indicated by the 
“MeetsCriteria” column. 
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Please note that this table has been uploaded as a separate file 
named SupplementaryTables.xlsx and can be found on the 
sheet labeled “TableS9 –Wilms development TFs” or in 
TableS9.xlsx 
Table S9. Transcription factors important to Wilms’ development 
The transcription factor changes that change significantly along either of the two branches from 
right to left in (Fig. 3C). The last three columns give the average expression from cells in the 
different nodes of the pseudotime trajectory in Fig. 3B. 
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SangerID PD_ID EGA_ID EGA_StudyID StudyTitle Experiment 
4496STDY6908196 PD36165b EGAN00001547798 EGAS00001002171 Orphan Tumour Study Wilms1 
4766STDY6993201 PD35918g EGAN00001561561 EGAS00001002486 Kidney tumour_DNA PapRCC 
4766STDY7061100 PD35918g EGAN00001586322 EGAS00001002486 Kidney tumour_DNA PapRCC 
4766STDY6993199 PD35918h EGAN00001561559 EGAS00001002486 Kidney tumour_DNA PapRCC 
4766STDY7061101 PD35918h EGAN00001586323 EGAS00001002486 Kidney tumour_DNA PapRCC 
4766STDY6993197 PD36165d EGAN00001561556 EGAS00001002486 Kidney tumour_DNA Wilms1 
4766STDY6993198 PD36165e EGAN00001561558 EGAS00001002486 Kidney tumour_DNA Wilms1 
4766STDY6993204 PD36793a EGAN00001561564 EGAS00001002486 Kidney tumour_DNA VHL_RCC 
4766STDY6993203 PD36793c EGAN00001561563 EGAS00001002486 Kidney tumour_DNA VHL_RCC 
4766STDY6993195 PD37104a EGAN00001561555 EGAS00001002486 Kidney tumour_DNA RCC1 
4766STDY6993196 PD37104b EGAN00001561557 EGAS00001002486 Kidney tumour_DNA RCC1 
4766STDY7061105 PD37228c EGAN00001586327 EGAS00001002486 Kidney tumour_DNA RCC2 
4766STDY7061102 PD37228f EGAN00001586324 EGAS00001002486 Kidney tumour_DNA RCC2 
4766STDY7061111 PD37272a EGAN00001586333 EGAS00001002486 Kidney tumour_DNA Wilms2 
4766STDY7061117 PD37272g EGAN00001586339 EGAS00001002486 Kidney tumour_DNA Wilms2 
4766STDY7061116 PD37276a EGAN00001586338 EGAS00001002486 Kidney tumour_DNA Wilms3 
4766STDY7061120 PD37276g EGAN00001586342 EGAS00001002486 Kidney tumour_DNA Wilms3 
Table S10. DNA manifest 
Table relating sample IDs used in experiment to other identifiers, including EGA accession 
number and study name.  This table pertains only to the bulk DNA samples. 
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Please note that this table has been uploaded as a separate file 
named SupplementaryTables.xlsx and can be found on the 
sheet labeled “TableS11 – Cell manifest” or in TableS11.xlsx 
Table S11. Cell manifest 
Summary of each cell identified in this experiment, which sample it originated from and which 
compartment and cluster it has been assigned to.  The column “Barcode” gives the 10X barcode 
for this cell, while the column “DropletID” prepends the sample ID to produce an ID which 
uniquely identifies each cell across all experiments.  nUMI gives the total number of UMIs 
detected in each cell, nGenes the total number of genes with non-zero expression and MTfrac 
gives the fraction of expression in each cell that comes from genes on the mitochondria.  Finally, 
“QCpass” indicates if this cell has passed all QC filters (see Methods). 
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PE Rabbit anti-human VEGFA, clone EP1176Y from abcam® (Cat# ab209439) 1/1000 dilution 
FITC Mouse anti-human CD68, clone KP1 from Dako antibodies (Cat# F7135) 1/200 dilution 
V450 Mouse anti-human HLA-DR, clone L243 from BD Biosciences (Cat# 
655874) 
1/100 dilution 
Alexa Fluor™ 647 Phalloidin (Cat# A22287) 1/100 dilution 
Primary Rabbit anti-human SLC17A3, polyclonal from abcam® (Cat# ab23332) 1/100 dilution 
Biotinylated Mouse anti-human CD106 (VCAM-1), clone STA from 
BioLegend® (Cat# 305804) 
1/100 dilution 
PE Mouse anti-human CA9, clone 303123 from R&D systems (Cat# FAB2188P) 1/100 dilution 
Alexa Fluor® 488 Donkey anti-rabbit IgG (H+L), polyclonal from ThermoFisher 
Scientific (Cat# A21206) 
1/200 dilution 
Streptavidin APC from ThermoFisher Scientific (Cat# 17-4317-82) 1/200 dilution 
Table S12. Antibodies and dilutions 
A table of the antibodies and dilutions used in performing the immunofluorescence microscopy. 
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Please note that these data have been uploaded  
as a separate file named DataS1.tar.gz 
Data S1 – Table of counts 
A table of counts for all candidate droplets (i.e., the 125,139 unique barcodes at the top of Fig. 
S1). Stored in matrix mart format along with two extra tables describing the column labels 
(droplets) and row labels (genes).  Counts represent number of unique UMIs for each 
gene/droplet pair (see Methods). 
 
